Frailty dynamics and their impact on <scp>QoL</scp> in patients undergoing autologous <scp>HCT</scp> for multiple myeloma: Results from a multicentre <scp>GETH</scp>‐<scp>TC</scp> study
This prospective multicentre study evaluates the utility of the haematopoietic cell transplantation (HCT) Frailty Scale in 269 adults with multiple myeloma (MM) undergoing autologous haematopoietic cell transplantation (auto-HCT). Frailty was assessed in all patients at the first consultation, at transplant admission and on day +100. Quality of life (QoL) was measured using the EuroQol (EQ-5D-5L) questionnaire. At the first consultation, 23.8% were fit, 57.6% pre-frail and 18.6% frail. Frailty was associated with advanced disease stage, reduced Karnofsky Performance Status and older age. At HCT admission, 32.3% of patients showed changes in frailty status, confirming its dynamic nature. Frail patients had higher readmission rates (14.7%) and significantly lower QoL (p < 0.001) compared to others. Although differences in non-relapsed mortality (NRM) were not statistically significant, frail and pre-frail patients showed higher 1-year NRM (4.8% and 3.4%) compared to fit patients (0%). By day +100, 33.6% were fit, 55.9% pre-frail and 8.2% frail, with frail patients continuing to report poorer QoL. In conclusion, the HCT Frailty Scale is a valuable tool for identifying and monitoring frailty in MM patients undergoing auto-HCT. As frailty status evolves over time, ongoing assessment is essential to guide personalized care, reduce complications and improve outcomes and QoL.
Authors
- Leyre Bento (ORCID: https://orcid.org/0000-0001-9929-8617)
- Esperanza Lavilla (ORCID: https://orcid.org/0000-0003-1490-0678)
- Sara Villar (ORCID: https://orcid.org/0000-0002-4761-6692)
- María Queralt Salas (ORCID: https://orcid.org/0000-0003-4567-3682)
- María del Carmen Quintela González
- Ana Raquel Santa-Maria (ORCID: https://orcid.org/0000-0003-3505-5477)
- María Laura Fox (ORCID: https://orcid.org/0000-0002-0062-6607)
- Sara Fernández‐Luis (ORCID: https://orcid.org/0000-0001-9630-5893)
- Albert Esquirol (ORCID: https://orcid.org/0000-0002-6062-5980)
- Javier Cornago Navascués
- Julia Ribes‐Amorós
- Joaquina M. Salmerón Camacho (ORCID: https://orcid.org/0000-0001-9094-1645)
- Isabel Izquierdo García
- Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
- Andrés Sánchez‐Salinas (ORCID: https://orcid.org/0000-0001-9495-3555)
- Javier López-Marín
- Marina Acera Gómez
- Ángel Cedillo (ORCID: https://orcid.org/0000-0002-0126-7044)
- Carles Tolosa (ORCID: https://orcid.org/0000-0003-0706-9046)
- Silvia Filaferro
- Zahra Abdallahi‐Lefdil
- Patricia Beorlegui‐Murillo
- Mónica Baile González
- Pascual Basalobre
- Laura Pardo
- Verónica Illana Álvaro
- Leddy Patricia Vega Suárez
- María del Mar Pérez Artigas
Institutions
- Hospital de Sant Pau (ES)
- University Hospital Complex Of Vigo (ES)
- Josep Carreras Leukaemia Research Institute (ES)
- Departament de Salut (ES)
- Grupo Español de Trasplante Hematopoyético y Terapia Celular (ES)
- Complejo Hospitalario de Salamanca (ES)
- Marqués de Valdecilla University Hospital (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Mútua Terrassa (ES)
- Hospital Universitario de La Princesa (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Clinica Universidad de Navarra (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Duran i Reynals Hospital (ES)
- Hospital Universitario Lucus Augusti (ES)
- Hospital Universitario Virgen de la Arrixaca (ES)
- Hospital Universitario Son Espases (ES)
- Complejo Hospitalario de Pontevedra (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1111/bjh.70068
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00